MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563258 | Name: SR3677
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SR3677 is an isoform-selective inhibitor of ROCK2 kinase activity.

Chemical Structure

SR3677
CAS#1072959-67-1

Theoretical Analysis

MedKoo Cat#: 563258

Name: SR3677

CAS#: 1072959-67-1

Chemical Formula: C22H24N4O4

Exact Mass: 408.1798

Molecular Weight: 408.45

Elemental Analysis: C, 64.69; H, 5.92; N, 13.72; O, 15.67

Price and Availability

Size Price Availability Quantity
5mg USD 450.00 2 weeks
10mg USD 750.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
SR3677; SR-3677; SR 3677;
IUPAC/Chemical Name
N-[2-[2-(Dimethylamino)ethoxy]-4-(1H-pyrazol-4-yl)phenyl]-2,3-dihydro-1,4-benzodioxine-3-carboxamide
InChi Key
OQWZIAVXCYIZNN-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H24N4O4/c1-26(2)9-10-28-20-11-15(16-12-23-24-13-16)7-8-17(20)25-22(27)21-14-29-18-5-3-4-6-19(18)30-21/h3-8,11-13,21H,9-10,14H2,1-2H3,(H,23,24)(H,25,27)
SMILES Code
O=C(C1COC2=CC=CC=C2O1)NC3=CC=C(C4=CNN=C4)C=C3OCCN(C)C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, DMF, and ethanol
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
SR3677 shows greater potency against ROCK2 than ROCK1 in enzyme and cell-based assays (IC50 values = 3 and 56 nM, respectively). At 3 µM, SR3677 inhibits only 5 (Akt3, Clk1, Clk2, Clk4, Lats2) out of 353 kinases with greater than 50% inhibition.
In vitro activity:
SR3677 had an IC50 of approximately 3 nM in enzyme and cell based assays and had an off-target hit rate of 1.4% against 353 kinases, and inhibited only 3 out of 70 nonkinase enzymes and receptors. Reference: J Med Chem. 2008 Nov 13;51(21):6642-5. https://pubmed.ncbi.nlm.nih.gov/18834107/
In vivo activity:
In Alzheimer's disease mouse brains, SR3677 suppressed β-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) enzymatic action and diminished production of Aβ. SR3677 blocked ROCK2 phosphorylation of APP at threonine 654 (T654); in neurons, T654 was critical for APP processing to Aβ. Reference: J Neurosci. 2013 Dec 4;33(49):19086-98. https://pubmed.ncbi.nlm.nih.gov/24305806/
Solvent mg/mL mM comments
Solubility
DMF 30.0 73.45
DMSO 30.0 73.45
Ethanol 5.0 12.24
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 408.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J Med Chem. 2008 Nov 13;51(21):6642-5. doi: 10.1021/jm800986w. Epub 2008 Oct 4. PMID: 18834107; PMCID: PMC3708311. 2. Kasahara DI, Mathews JA, Park CY, Cho Y, Hunt G, Wurmbrand AP, Liao JK, Shore SA. ROCK insufficiency attenuates ozone-induced airway hyperresponsiveness in mice. Am J Physiol Lung Cell Mol Physiol. 2015 Oct 1;309(7):L736-46. doi: 10.1152/ajplung.00372.2014. Epub 2015 Aug 14. PMID: 26276827; PMCID: PMC4593838. 3. Herskowitz JH, Feng Y, Mattheyses AL, Hales CM, Higginbotham LA, Duong DM, Montine TJ, Troncoso JC, Thambisetty M, Seyfried NT, Levey AI, Lah JJ. Pharmacologic inhibition of ROCK2 suppresses amyloid-β production in an Alzheimer's disease mouse model. J Neurosci. 2013 Dec 4;33(49):19086-98. doi: 10.1523/JNEUROSCI.2508-13.2013. PMID: 24305806; PMCID: PMC3850036.
In vitro protocol:
1. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J Med Chem. 2008 Nov 13;51(21):6642-5. doi: 10.1021/jm800986w. Epub 2008 Oct 4. PMID: 18834107; PMCID: PMC3708311. 2. Kasahara DI, Mathews JA, Park CY, Cho Y, Hunt G, Wurmbrand AP, Liao JK, Shore SA. ROCK insufficiency attenuates ozone-induced airway hyperresponsiveness in mice. Am J Physiol Lung Cell Mol Physiol. 2015 Oct 1;309(7):L736-46. doi: 10.1152/ajplung.00372.2014. Epub 2015 Aug 14. PMID: 26276827; PMCID: PMC4593838.
In vivo protocol:
1. Herskowitz JH, Feng Y, Mattheyses AL, Hales CM, Higginbotham LA, Duong DM, Montine TJ, Troncoso JC, Thambisetty M, Seyfried NT, Levey AI, Lah JJ. Pharmacologic inhibition of ROCK2 suppresses amyloid-β production in an Alzheimer's disease mouse model. J Neurosci. 2013 Dec 4;33(49):19086-98. doi: 10.1523/JNEUROSCI.2508-13.2013. PMID: 24305806; PMCID: PMC3850036.
1: Vercammen H, Ondra M, Kotulova J, De La Hoz EC, Witters C, Jecmenova K, Le Compte M, Deben C, Ní Dhubhghaill S, Koppen C, Hajdúch M, Van den Bogerd B. "Keep on ROCKIn": Repurposed ROCK inhibitors to boost corneal endothelial regeneration. Biomed Pharmacother. 2024 May;174:116435. doi: 10.1016/j.biopha.2024.116435. Epub 2024 Mar 20. PMID: 38513591. 2: Santos GL, Hartmann S, Zimmermann WH, Ridley A, Lutz S. Inhibition of Rho- associated kinases suppresses cardiac myofibroblast function in engineered connective and heart muscle tissues. J Mol Cell Cardiol. 2019 Sep;134:13-28. doi: 10.1016/j.yjmcc.2019.06.015. Epub 2019 Jun 22. PMID: 31233754. 3: Vieira GM, Roberto GM, Lira RC, Engel EE, Tone LG, Brassesco MS. Prognostic value and functional role of ROCK2 in pediatric Ewing sarcoma. Oncol Lett. 2018 Feb;15(2):2296-2304. doi: 10.3892/ol.2017.7571. Epub 2017 Dec 8. PMID: 29434937; PMCID: PMC5777092. 4: Kasahara DI, Mathews JA, Park CY, Cho Y, Hunt G, Wurmbrand AP, Liao JK, Shore SA. ROCK insufficiency attenuates ozone-induced airway hyperresponsiveness in mice. Am J Physiol Lung Cell Mol Physiol. 2015 Oct 1;309(7):L736-46. doi: 10.1152/ajplung.00372.2014. Epub 2015 Aug 14. PMID: 26276827; PMCID: PMC4593838. 5: Herskowitz JH, Feng Y, Mattheyses AL, Hales CM, Higginbotham LA, Duong DM, Montine TJ, Troncoso JC, Thambisetty M, Seyfried NT, Levey AI, Lah JJ. Pharmacologic inhibition of ROCK2 suppresses amyloid-β production in an Alzheimer's disease mouse model. J Neurosci. 2013 Dec 4;33(49):19086-98. doi: 10.1523/JNEUROSCI.2508-13.2013. PMID: 24305806; PMCID: PMC3850036. 6: Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P. Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors. J Med Chem. 2008 Nov 13;51(21):6642-5. doi: 10.1021/jm800986w. Epub 2008 Oct 4. PMID: 18834107; PMCID: PMC3708311.